Compare Godaddy Inc (GDDY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Novavax Inc — how do they compare? Godaddy Inc trades at $104.37 (market cap $13.07B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Godaddy Inc is far larger — about 7.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and Novavax Inc for 59 Days on average.
| GDDY | NVAX | |
|---|---|---|
Market Cap | $13.07B | $1.82B |
Volume | 1,831,274 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $135.18 | $12.56 |
52-Week Low | $75.07 | $6.22 |
Typical Hold Time | 64 Days | 59 Days |
Enterprise Value | $15.75B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $104.37, up 7.37% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and revenue growth to $4.95 billion in 2025. However, a class action lawsuit filed in September 2026 alleging securities fraud during September 2025 to February 2026 has created negative sentiment, though analyst consensus remains predominantly buy-rated.
The outlook is mixed; strong profitability and consistent earnings beats support upside potential, but legal risks and a current price above the $96.20 consensus target warrant caution. Key risks include litigation outcomes and competitive pressures in web services, while institutional analyst support at 57.9% buy ratings provides a cushion against near-term volatility.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
